Radius Ventures

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Impliant Ltd. and over $50 million have been invested in laboratory testing and clinical work to perfect the implant, the instrumentation, and the surgical technique. The TOPS(TM) System aims to revolutionize the spinal implant market in much the same way that total hip and total knee replacement systems displaced hip and knee fusions. Premia Spine's singular focus today is to provide patients and surgeons with a clinically-proven superior solution to lumbar fusion surgery.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

CareKinesis, Inc. provides state-of-the-art medication management through a combination of technology, science and services that reduces costs, improves the quality of care and decreases the risks associated with ineffective medication plans.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Tactile Systems Technology is a Minneapolis, Minnesota-based company, dedicated to advancing the standard of care in treating edema and vascular diseases at home. They manufacture and market the Flexitouch® system, an innovative medical device developed for at–home treatment of lymphedema, chronic edema, and non–healing venous ulcers.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incision-less surgical technology for the treatment of GERD.

Healthsense is a provider of remote monitoring technology solutions for the senior care continuum. With our full range of health and safety monitoring systems, providers are empowered to proactively deliver the highest quality care possible through critical health information. Caregivers reduce costs, increase independence and enhance senior experiences when armed with the right information at the right time.

Management Health Solutions, Inc. (MHS) is the leading provider of an integrated inventory management solution designed to dramatically reduce clinical supply inventory cost and streamline clinical supply chain operations, which enhances patient safety and improves financial performance. MHS combines 'best-in-class' professional services with content solutions, benchmarks, leading-edge technology, and mobile device management enabling hospitals to generate a measurable return on investment. MHS serves individual hospitals and integrated delivery networks in North America. The company was established in 1999 and is headquartered in Fairfield, Connecticut, United States.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Medingo develops and produces miniature medical devices for people with diabetes. The company's flagship product is the Solo MicroPump, a tiny insulin pump that allows people with diabetes to deliver insulin discreetly without tubing or needles. The company was founded in 2005 and is based in Yoqneam Illit, Israel and the US Corporate Office is in Tampa, FL.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

USystems specializes in the design, development, and manufacturing of advanced technology solutions in two primary sectors: medical imaging and data center infrastructure. In the medical field, the company creates innovative breast ultrasound systems that aid radiologists in detecting breast cancer, particularly in women with dense breast tissue, by providing detailed 3D ultrasound images for improved visualization. In the realm of data centers, USystems manufactures cooling systems that enhance sustainability while reducing noise and heat. Their offerings include air-cooled and soundproof rapid deployment micro data centers equipped with intelligent features, such as real-time alarms and optional security monitoring, to safeguard IT equipment and optimize operational efficiency. Through its cutting-edge designs and state-of-the-art manufacturing processes, USystems is committed to delivering high-quality solutions that address critical challenges in both healthcare and information technology.

Athersys is a biopharmaceutical company that discovers and develops therapeutic products to treat several disease indications. The company's product development portfolio includes MultiStem, a stem cell product, that is being developed as a treatment for multiple disease indications, is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, Athersys develops pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy, or other forms of excessive daytime sleepiness.

BioStorage Technologies is the premier, global provider of comprehensive sample management solutions for the bioscience industry BioStorage Technologies, Inc. was founded in 2002 and is privately held and headquartered in North America in Indianapolis, Indiana with an additional full-service site in Europe near Frankfurt, Germany. Their mission is to provide their clients with world class, biorepository services, exceeding clients’ expectations of service, value and quality while setting the industry standard for the storage, management & logistics of samples.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

EyeTel Imaging was founded in 1996 and began operations when it signed a license agreement with Johns Hopkins University to develop and commercialize a new technology for retinal imaging. EyeTel was started with the idea of using new imaging technologies to address the large, growing and addressable clinical problem of vision loss due to undetected and untreated diabetic retinopathy. The key tenets of the EyeTel Philosophy were established in those early days and are the foundation of their company: - World class technology that has extensive clinical validation - Along with expert clinical support - For use in the primary care setting to provide better care conveniently for patients - In a cost effective and easy to use way EyeTel worked in collaboration with the scientists from the Wilmer Eye Institute to develop the DigiScope, a semi-automated fundus camera with telemedicine capabilities. A patent covering the technology was granted and they filed a 510(k) for the DigiScope and received FDA clearance in 1999. A validation study independent of Wilmer was conducted at Henry Ford Hospital in Detroit, MI under the direction of Rhett Schiffman, M.D. The results of the study were published in Ophthalmic Surgery, Lasers and Imaging and demonstrated excellent agreement, sensitivity and specificity compared with the gold standard seven-field color stereo photography for identifying patients with any levels of diabetic retinopathy. As they grew, they created the EyeTel Reading Center, a world-class telemedicine service providing expert analysis of patient images by highly trained "readers". The Wilmer Eye Institute provides clinical and quality oversight for the EyeTel Reading Center. They also established a manufacturing agreement with Topzone of Changsha, China to manufacture the DigiScope. This arrangement allows EyeTel to produce the DigiScope at low cost and provides a scalable source of DigiScope production. After an extensive worldwide search, Eli Lilly a leader in diabetes research, chose EyeTel to collaborate on market development for identifying patients with diabetic retinopathy. By 2007, their development work, with the scientists and clinical experts from Wilmer and with their manufacturing and development partner in China, led to significant enhancements to the capabilities of the EyeTel Retinal Imaging System making it a robust tool to help the Optometric physician detect age-related macular degeneration, optic disc abnormalities such as glaucoma, as well as diabetic retinopathy. True to their founding principles, the enhanced EyeTel Retinal Imaging System for the optometric practice remains easy to use, cost effective, and has been extensively validated in clinical settings to ensure it's efficacy as a diagnostic tool for the practicing Optometric physician.

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.

EyeTel Imaging was founded in 1996 and began operations when it signed a license agreement with Johns Hopkins University to develop and commercialize a new technology for retinal imaging. EyeTel was started with the idea of using new imaging technologies to address the large, growing and addressable clinical problem of vision loss due to undetected and untreated diabetic retinopathy. The key tenets of the EyeTel Philosophy were established in those early days and are the foundation of their company: - World class technology that has extensive clinical validation - Along with expert clinical support - For use in the primary care setting to provide better care conveniently for patients - In a cost effective and easy to use way EyeTel worked in collaboration with the scientists from the Wilmer Eye Institute to develop the DigiScope, a semi-automated fundus camera with telemedicine capabilities. A patent covering the technology was granted and they filed a 510(k) for the DigiScope and received FDA clearance in 1999. A validation study independent of Wilmer was conducted at Henry Ford Hospital in Detroit, MI under the direction of Rhett Schiffman, M.D. The results of the study were published in Ophthalmic Surgery, Lasers and Imaging and demonstrated excellent agreement, sensitivity and specificity compared with the gold standard seven-field color stereo photography for identifying patients with any levels of diabetic retinopathy. As they grew, they created the EyeTel Reading Center, a world-class telemedicine service providing expert analysis of patient images by highly trained "readers". The Wilmer Eye Institute provides clinical and quality oversight for the EyeTel Reading Center. They also established a manufacturing agreement with Topzone of Changsha, China to manufacture the DigiScope. This arrangement allows EyeTel to produce the DigiScope at low cost and provides a scalable source of DigiScope production. After an extensive worldwide search, Eli Lilly a leader in diabetes research, chose EyeTel to collaborate on market development for identifying patients with diabetic retinopathy. By 2007, their development work, with the scientists and clinical experts from Wilmer and with their manufacturing and development partner in China, led to significant enhancements to the capabilities of the EyeTel Retinal Imaging System making it a robust tool to help the Optometric physician detect age-related macular degeneration, optic disc abnormalities such as glaucoma, as well as diabetic retinopathy. True to their founding principles, the enhanced EyeTel Retinal Imaging System for the optometric practice remains easy to use, cost effective, and has been extensively validated in clinical settings to ensure it's efficacy as a diagnostic tool for the practicing Optometric physician.

ZettaCore is pioneering the field of molecular electronics. The company is focused on developing molecular materials to service the electronics industry. Their unique chemistry leverages the existing manufacturing infrastructure and enables the transition to higher performance at lower cost.

NuGEN is a provider of innovative genomics sample preparation solutions enabling scientists to access true biology in all samples, independent of type, quality and amount for analysis on leading analytical platforms. Committed to advancing the life sciences, NuGEN ensures robust and reproducible results for researchers seeking to predict disease risk and drug response, potentially shortening the path to treatment.

Health Language provides enterprise terminology management solutions and professional services that normalize data within healthcare organizations. It offers health management software, content, and consulting solutions that map, translate, update, and manage clinical terminologies on an enterprise scale. The company provides healthcare IT solutions in the areas of content standardization, data normalization, ICD-10 remediation, and workflow-enhancing search. It also serves payers, providers, and vendors. Health Language was founded in 2000 and is based in Denver, Colorado.

ZettaCore is pioneering the field of molecular electronics. The company is focused on developing molecular materials to service the electronics industry. Their unique chemistry leverages the existing manufacturing infrastructure and enables the transition to higher performance at lower cost.

NuGEN is a provider of innovative genomics sample preparation solutions enabling scientists to access true biology in all samples, independent of type, quality and amount for analysis on leading analytical platforms. Committed to advancing the life sciences, NuGEN ensures robust and reproducible results for researchers seeking to predict disease risk and drug response, potentially shortening the path to treatment.

TheScientificWorld is a scientific information portal that provides an integrated suite of scientific resources for scientists. The company was founded in 1997 and is headquartered in New York.

AMICAS, Inc. provides radiology, and medical image and information management solutions in the United States. Its AMICAS One Suite products provide an end-to-end IT solution for imaging centers, ambulatory care facilities, radiology practices, and billing services. The company offers AMICAS PACS, a Web-based picture archiving and communications system to capture, store, manipulate, and distribute diagnostic images for radiologists, specialists, referring physicians, patients, and healthcare enterprises; and AMICAS RIS, a Web-based radiology information system to capture radiology orders, detail the patient demographic information, schedule appointments and resources, process transcriptions, and generate reports, as well as to code and prepare billing and reimbursement data. It also provides AMICAS RadStream that offers integrated critical results management capabilities and document the communication of critical results reporting of radiology studies; AMICAS Documents, a module to capture, digitize, and associate paper records with digital information; and AMICAS Financials, which facilitates claims submission, payer follow-up, and other billing and accounts receivable management activities. In addition, the company offers AMICAS Reach, a Web-based tool that integrates the radiology report with key images; AMICAS Dashboards, a Web-based system that provides business intelligence capabilities; and AMICAS EDI offering transaction-based functions. Further, it provides professional and consulting services that assist its clients with a planned transition to a digital enterprise, as well as offers software and hardware support, implementation, training, and electronic data interchange services for patient billing and claims processing. The company was formerly known as VitalWorks Inc. and changed its name to AMICAS, Inc. in January 2005. AMICAS, Inc. was founded in 1989 and is headquartered in Boston, Massachusetts.